Vitamin D has a potential role in preventing HIV-related complications, based on its extensive involvement in immune and metabolic function, including preventing osteoporosis and premature cardiovascular disease. However, this association has not been examined in large studies or in resource-limited settings. Vitamin D levels were assessed in 884 HIV-infected pregnant women at enrollment in a trial of multivitamin supplementation (excluding vitamin D) in Tanzania. Information on HIV related complications was recorded during follow-up (median, 70 months). Proportional hazards models and generalized estimating equations were used to assess the relationship of vitamin D status with these outcomes. Women with low vitamin D status (serum 25-hydroxyvitamin D<32 ng/mL) had 43% higher risk of reaching a body mass index (BMI) less than 18 kg/m2 during the first 2 years of follow-up, compared to women with adequate vitamin D levels (hazard ratio [HR]: 1.43; 95% confidence intervals: [1.03–1.99]). The relationship between continuous vitamin D levels and risk of BMI less than 18 kg/m2 during follow-up was inverse and linear (p=0.03). Women with low vitamin D levels had significantly higher incidence of acute upper respiratory infections (HR: 1.27 [1.04–1.54]) and thrush (HR: 2.74 [1.29-5.83]) diagnosed during the first 2 years of follow-up. Low vitamin D status was a significant risk factor for wasting and HIV-related complications such as thrush during follow-up in this prospective cohort in Tanzania. If these protective associations are confirmed in randomized trials, vitamin D supplementation could represent a simple and inexpensive method to improve health and quality of life of HIV-infected patients, particularly in resource-limited settings.
Get full access to this article
View all access options for this article.
References
1.
AdamsJS, LiuPT, ChunR, ModlinRL, HewisonM. Vitamin D in defense of the human immune response. Ann NY Acad Sci, 2007; 1117:94–105.
2.
deLucaHF. Metabolism and molecular mechanism of action of vitamin D: 1981. Biochem Soc Trans, 1982; 10:147–158.
3.
StroderJ. Immunity In Vitamin D Deficient Rickets. Vitamin D And Problems Of Uremic Bone Disease. Berlin: de Gruyter, 1975; 675–687.
4.
LiuPT, StengerS, TangDH, ModlinRL. Cutting edge: Vvitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol, 2007; 179:2060–2063.
5.
LiuPT, StengerS, LiHet al.Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006; 311:1770–1773.
6.
Bischoff-FerrariHA. Vitamin D and fracture prevention. Endocrinol Metab Clin North Am, 2010; 39:347–353table of contents.
7.
Bischoff-FerrariHA, ShaoA, Dawson-HughesB, HathcockJ, GiovannucciE, WillettWC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int, 2010; 21:1121–1132.
8.
SouberbielleJC, BodyJJ, LappeJMet al.Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev, 2010; 9:709–715.
9.
WangL, MansonJE, SongY, SessoHD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med, 2010; 152:315–323.
10.
LiYC, QiaoG, UskokovicM, XiangW, ZhengW, KongJ. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol, 2004; 89–90:387–392.
11.
ParkerJ, HashmiO, DuttonDet al.Levels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis. Maturitas, 2010; 65:225–236.
12.
FawziWW, MsamangaGI, SpiegelmanDet al.A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med, 2004; 351:23–32.
13.
MehtaS, GiovannucciE, MugusiFMet al.Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE, 2010; 5:e8770.
14.
FawziWW, MsamangaGI, SpiegelmanD, UrassaEJ, HunterDJ. Rationale and design of the Tanzania Vitamin and HIV Infection Trial. Control Clin Trials, 1999; 20:75–90.
15.
WHO. Proposed ‘World Health Organization staging system for HIV infection and disease’: Preliminary testing by an international collaborative cross-sectional study. The WHO International Collaborating Group for the Study of the WHO Staging System. AIDS, 1993; 7:711–718.
16.
UrassaW, MatundaS, Bredberg-RadenU, MhaluF, BiberfeldG. Evaluation of the WHO human immunodeficiency virus (HIV) antibody testing strategy for the diagnosis of HIV infection. Clin Diagn Virol, 1994; 2:1–6.
17.
HollisBW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr, 2005; 135:317–322.
18.
BodnarLM, SimhanHN, PowersRW, FrankMP, CoopersteinE, RobertsJM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr, 2007; 137:447–452.
19.
VillamorE, SaathoffE, ManjiK, MsamangaG, HunterDJ, FawziWW. Vitamin supplements, socioeconomic status, and morbidity events as predictors of wasting in HIV-infected women from Tanzania. Am J Clin Nutr, 2005; 82:857–865.
20.
van der SandeMA, Schim van der LoeffMF, AveikaAAet al.Body mass index at time of HIV diagnosis: A strong and independent predictor of survival. J Acquir Immune Defic Syndr, 2004; 37:1288–1294.
21.
JamesWP, Mascie-TaylorGC, NorganNG, BistrianBR, ShettyPS, Ferro-LuzziA. The value of arm circumference measurements in assessing chronic energy deficiency in Third World adults. Eur J Clin Nutr, 1994; 48:883–894.
22.
WankeC, KotlerD. Collaborative recommendations: The approach to diagnosis and treatment of HIV wasting. J Acquir Immune Defic Syndr, 2004; 37:S284–S288.
23.
PolskyB, KotlerD, SteinhartC. HIV-associated wasting in the HAART era: Guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDs, 2001; 15:411–423.
24.
CoxD. Regression models and life tables. J R Stat Soc, 1972; 34:187–220.
25.
GovindarajuluUS, SpiegelmanD, ThurstonSW, GanguliB, EisenEA. Comparing smoothing techniques in Cox models for exposure-response relationships. Stat Med, 2007; 26:3735–3752.
26.
DurrlemanS, SimonR. Flexible regression models with cubic splines. Stat Med, 1989; 8:551–561.
27.
DiggleP, LiangKY, ZegerSL. Analysis of Longitudinal Data. Oxford, England: Oxford University Press, 1995.
28.
GreenlandS. Modeling and variable selection in epidemiologic analysis. Am J Public Health, 1989; 79:340–349.
29.
MiettinenO. Theoretical Epidemiology, 107. New York: John Wiley & Sons, 1985.
30.
MuellerNJ, FuxCA, LedergerberBet al.High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS, 2010; 24:1127–1134.
31.
BangUC, ShakarSA, HitzMFet al.Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: A descriptive cross-sectional study. Scand J Infect Dis, 2010; 42:306–310.
32.
OvertonET, YinMT. The rapidly evolving research on vitamin D among HIV-infected populations. Curr Infect Dis Rep, 2011; 13:83–93.
33.
WassermanP, RubinDS. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDs, 2010; 24:223–227.
34.
DaoCN, PatelP, OvertonETet al.Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis, 2011; 52:396–405.
35.
SteinEM, YinMT, McMahonDJet al.Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int, 2011; 22:477–487.
36.
AdeyemiOM, AgnielD, FrenchALet al.Vitamin D deficiency in HIV-infected and un-infected women in the US. J Acquir Immune Defic Syndr(in press).
37.
FinkelsteinJL, MugusiFM, MehtaS, FawziWW. HIV/AIDS and nutrition in the era of antiretroviral therapy: Programmatic implications for care and treatment. MarlinkRG, TeitelmanSJ. From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings. Washington, D.C.: Elizabeth Glaser Pediatric AIDS Foundation, 2009; 2:193–229.
38.
PalenicekJP, GrahamNM, HeYDet al.Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr Hum Retrovirol, 1995; 10:366–373.
39.
HsuJW, PencharzPB, MacallanDC, TomkinsA. Macronutrients and HIV/AIDS: a review of current evidence. Durban, South Africa: World Health Organization, April10–13, 2005.
40.
GuenterP, MuurahainenN, SimonsGet al.Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr, 1993; 6:1130–1138.
41.
ChlebowskiRT, GrosvenorMB, BernhardNH, MoralesLS, BulcavageLM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol, 1989; 84:1288–1293.
42.
RimaniolAC, ZylberbergH, ZavalaF, ViardJP. Inflammatory cytokines and inhibitors in HIV infection: Correlation between interleukin-1 receptor antagonist and weight loss. AIDS, 1996; 10:1349–1356.
43.
GodfriedMH, van der PollT, JansenJet al.Soluble receptors for tumour necrosis factor: A putative marker of disease progression in HIV infection. AIDS, 1993; 7:33–36.
44.
AcharyyaS, LadnerKJ, NelsenLLet al.Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest, 2004; 114:370–378.
45.
TraceyKJ, BeutlerB, LowrySFet al.Shock and tissue injury induced by recombinant human cachectin. Science, 1986; 234:470–474.
46.
ZhangZ, YuanW, SunLet al.1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int, 2007; 72:193–201.
47.
TeegardenD, DonkinSS. Vitamin D: Emerging new roles in insulin sensitivity. Nutr Res Rev, 2009; 22:82–92.
48.
SunJ, KongJ, DuanYet al.Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab, 2006; 291:E315–322.
49.
LavernyG, PennaG, VetranoSet al.Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett, 2010; 131:49–58.
50.
Cohen-LahavM, ShanyS, TobvinD, ChaimovitzC, DouvdevaniA. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant, 2006; 21:889–897.
51.
Cohen-LahavM, DouvdevaniA, ChaimovitzC, ShanyS. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol, 2007; 103:558–562.
52.
AdamsLS, TeegardenD. 1,25-dihydroxycholecalciferol inhibits apoptosis in C3H10T1/2 murine fibroblast cells through activation of nuclear factor kappaB. J Nutr, 2004; 134:2948–2952.
53.
SpectorSA. Vitamin D earns more than a passing grade. J Infect Dis, 2009; 200:1015–1017.
